Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder

期刊论文
出版模式：

开放获取
发表日期：

2024年6月18日

查看全文

Pouya Azar,
Hannah Schneiderman,
Henry Barron,
James S. H. Wong,
Maximilian Meyer,
Dayyon Newman-Azar,
Matin Narimani,
Martha J. Ignaszewski,
Nickie Mathew,
Rodney Mullen,
Reinhard M. Krausz,
Anil R. Maharaj

摘要

Background

Buprenorphine is an effective and safe treatment for opioid use disorder, but the requirement for moderate opioid withdrawal symptoms to emerge prior to initiation is a significant treatment barrier.

Case Presentation

We report on two cases of hospitalized patients with severe, active opioid use disorder, in which we initiated treatment with transdermal buprenorphine over 48 h, followed by the administration of a single dose of sublingual buprenorphine/naloxone and then extended-release subcutaneous buprenorphine. The patients did not experience precipitated withdrawal and only had mild withdrawal symptoms.

Conclusions

This provides preliminary evidence for a rapid induction strategy that may improve tolerability, caregiver burden, and treatment retention as compared to previous induction strategies.